A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Subjects With Psoriasis
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs PRX 003 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors Prothena
- 08 Aug 2017 According to a Prothena media release, top-line results from this trial are expected in October 2017.
- 05 Jul 2016 According to Prothena Corporation media release, interim data expected by mid-2017.
- 03 May 2016 According to a Prothena media release, topline results from this trial are expected in the second half of 2017.